Letrozole for Ovulation Induction in PCOS
Letrozole at 2.5 mg daily for 5 days (cycle days 3-7) is the recommended starting dose for ovulation induction in women with PCOS, with dose escalation to 5 mg or 7.5 mg in subsequent cycles if ovulation does not occur. 1, 2
Starting Protocol
- Initial dose: 2.5 mg orally once daily for 5 days, typically starting on cycle day 3 3, 4
- Administration: Can be taken without regard to meals 3
- Monitoring: Transvaginal ultrasound to assess follicular development approximately 7-10 days after the last letrozole dose 5
Dose Escalation Strategy
If ovulation does not occur with the initial 2.5 mg dose, escalate sequentially in subsequent cycles:
Higher starting doses (5 mg) or extended duration (10 days) significantly shorten time to ovulation and pregnancy compared to the standard 2.5 mg for 5 days regimen. 1 Specifically, starting with 5 mg for 5 days increases ovulation odds 3.4-fold, while 5 mg for 10 days increases odds 5.9-fold compared to 2.5 mg for 5 days 1. However, the conservative approach of starting at 2.5 mg remains reasonable to minimize potential risks.
Management of Letrozole Resistance
For patients who fail to develop a dominant follicle after 7.5 mg letrozole for 5 days:
- Add dexamethasone: Continue letrozole 7.5 mg for 5 additional days with low-dose dexamethasone 0.5 mg daily for 7 days 5
- This combination achieves ovulation in 79% of letrozole-resistant patients with a 20% clinical pregnancy rate per ovulatory cycle 5
Alternatively, consider:
- Sequential letrozole/gonadotropin: Adding gonadotropins after letrozole improves both ovulation and clinical pregnancy rates compared to letrozole alone 6
Expected Outcomes
Ovulation rates with dose escalation:
Cumulative ovulation rates exceed 84% across all dosing regimens 1, with pregnancy rates of 20-42% depending on the protocol 7, 8
Advantages Over Clomiphene Citrate
Letrozole demonstrates superior outcomes compared to clomiphene citrate:
- Higher pregnancy rates: 42% vs 20% 7
- Shorter time to pregnancy: 9.7 weeks vs 11.1 weeks 7
- Better endometrial development: Mean thickness 9.9 mm vs 9.4 mm 7
- More monofollicular development: 68% vs 45% of cycles, reducing multiple pregnancy risk 7
Critical Safety Considerations
Pregnancy testing is mandatory before each treatment cycle 3. Letrozole causes fetal harm based on animal studies, including skeletal malformations and embryo-fetal toxicity 3.
- Contraception required: Effective contraception must be used during treatment and for at least 3 weeks after the last dose 3
- Breastfeeding contraindicated: Do not breastfeed during treatment and for 3 weeks after the last dose 3
Dose Adjustment for Hepatic Impairment
Patients with cirrhosis or severe hepatic impairment: Reduce dose to 2.5 mg every other day 3
Common Pitfalls to Avoid
- Do not combine letrozole with clomiphene citrate as first-line therapy: The combination does not significantly improve ovulation, pregnancy, or live birth rates compared to letrozole alone 8
- Avoid premature escalation: Allow adequate time for follicular response assessment before declaring treatment failure
- Monitor for multifollicular development: While letrozole has lower risk than clomiphene, multiple follicles can still develop, particularly at higher doses 1, 7
- Do not use extended duration (10 days) routinely as first-line: Reserve for non-responders, as standard 5-day protocols are effective for most patients 9
Phenotype Considerations
All PCOS phenotypes (A, B, C, D) respond similarly to escalating letrozole doses, so phenotypic subcategorization does not predict differential response and should not guide initial dosing decisions 2.